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Angiotensin-converting enzyme 2 (ACE2) degrades angiotensin (Ang) II to Ang-(1–7),
and protects against diabetic renal injury. Soluble ACE2 fragments are shed from the
proximal tubule, and appear at high levels in the urine with diabetes. High glucose-
induced shedding of ACE2 from proximal tubular cells is mediated by the enzyme “a
disintegrin and metalloproteinase-17′′ (ADAM17). Here, we investigated the mechanism
for constitutive shedding of ACE2. Mouse proximal tubular cells were cultured and
ACE2 shedding into the media was assessed by enzyme activity assay and immunoblot
analysis. Cells were incubated with pharmacologic inhibitors, or transfected with
silencing (si) RNA. Incubation of proximal tubular cells with increasing concentrations
of D-glucose stimulated ACE2 shedding, which peaked at 16 mM, while L-glucose
(osmotic control) had no effect on shedding. In cells maintained in 7.8 mM D-glucose,
ACE2 shedding was significantly inhibited by the pan-protein kinase C (PKC) competitive
inhibitor sotrastaurin, but not by an inhibitor of ADAM17. Incubation of cells with
the PKC-α and -β1-specific inhibitor Go6976, the PKC β1 and β2-specific inhibitor
ruboxistaurin, inhibitors of matrix metalloproteinases-2,-8, and -9, or an inhibitor of
ADAM10 (GI250423X) had no effect on basal ACE2 shedding. By contrast, the PKC-δ
inhibitor rottlerin significantly inhibited both constitutive and high glucose-induced ACE2
shedding. Transfection of cells with siRNA directed against PKC-δ reduced ACE2
shedding by 20%, while knockdown of PKC-ε was without effect. These results
indicate that constitutive shedding of ACE2 from proximal tubular cells is mediated by
PKC-δ, which is also linked to high glucose-induced shedding. Targeting PKC-δ may
preserve membrane-bound ACE2 in proximal tubule in disease states and diminish Ang
II-stimulated adverse signaling.
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INTRODUCTION
The renal proximal tubular renin-angiotensin system (RAS) is activated in pathogenic states such as
diabetic nephropathy, and enhanced generation of the vasoconstrictor peptide angiotensin (Ang)
II contributes to progressive nephron injury. Thus, Ang II causes cell hypertrophy, reactive oxygen
species generation, inflammation, and apoptosis in proximal tubule, which promote development
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of chronic tubulointerstitial fibrosis (Sachse and Wolf, 2007).
To counteract RAS activation, the proximal tubule expresses
angiotensin-converting enzyme 2 (ACE2), a type I membrane
protein localized primarily to the apical membrane, where it
cleaves the carboxy-terminal amino acid of Ang II to form the
heptapeptide Ang-(1–7) (Warner et al., 2005; Shaltout et al.,
2007). Not only does ACE2 reduce local levels of Ang II, but
the generation of Ang-(1–7) may provide renoprotection via
interaction with its Mas receptor (Santos et al., 2003), inducing
downstream inhibition of Ang II signaling responses (Su et al.,
2006). Thus, gene deletion of ACE2 or pharmacologic ACE2
inhibition worsens albuminuria and promotes loss of renal
function in diabetic mouse models (Soler et al., 2007; Wong et al.,
2007), while overexpression of ACE2 or exogenous delivery of
human recombinant ACE2 to diabetic mice reduces albuminuria
and kidney injury (Oudit et al., 2010; Nadarajah et al., 2012).
Furthermore, studies in kidney biopsy specimens from humans
with diabetic nephropathy reveal diminished expression of ACE2
in glomeruli and tubular components, suggesting that loss of
ACE2 may contribute to disease progression (Reich et al.,
2008).
Soluble active fragments of ACE2 appear in the urine in
subjects with diabetes and chronic kidney disease (Mizuiri et al.,
2011; Xiao et al., 2012; Park et al., 2013; Cherney et al., 2014),
and are thought to be shed from proteolytic cleavage of the
ACE2 ectodomain. These studies implicate urinary ACE2 as
a potential biomarker of early diabetic nephropathy. In this
regard, we have demonstrated that ACE2 cleavage in mouse
proximal tubular cells in conditions of high glucose involves
activation of a disintegrin and metalloproteinase 17 (ADAM17),
a zinc-dependent protease also known as tumor necrosis factor-
α-converting enzyme (TACE) (Xiao et al., 2014). ADAM17 not
only cleaves ACE2, but is also involved as a sheddase enzyme
for other target proteins, including tumor necrosis factor-α and
epidermal growth factor (EGF) receptor ligands (Hinkle et al.,
2004). ACE2 cleavage by ADAM17 has also been demonstrated
in cultured HEK293, HK-2 proximal tubular, Huh7, COS7, and
human respiratory epithelial cells (Lambert et al., 2005; Jia et al.,
2009; Salem et al., 2014; Grobe et al., 2015). In diabetic Akita mice,
insulin treatment decreases renal ADAM17 protein expression,
associated with reduced urinary ACE2 shedding (Salem et al.,
2014). In diabetic states therefore, ADAM17 activation may be
responsible for increased urinary shedding of ACE2.
In addition to the ADAM family of metalloproteases,
ectodomain shedding of proteins may be regulated by several
stimuli, including protein kinase C (PKC), calcium ionophores,
G-protein-coupled receptors, and mitogen-activated protein
kinases (Murphy, 2009). Indeed, ADAM17 is considered to be
the major sheddase responsive to PKC stimulation by phorbol
esters (Kveiborg et al., 2011). However, in our previous studies we
showed that while ADAM17 is involved in the shedding of ACE2
fragments from proximal tubular cells in conditions of high
glucose, constitutive (basal) shedding of ACE2 is not affected by
inhibition of ADAM17 (Xiao et al., 2014). Therefore the purpose
of the present studies was to explore the mechanisms responsible
for constitutive shedding of ACE2 from proximal tubule. Our
results reveal that the PKC-δ isoform is a master regulator of
both constitutive and high glucose-stimulated shedding of ACE2
fragments from cultured mouse proximal tubular cells.
MATERIALS AND METHODS
Primary Cultures of Mouse Proximal
Tubular Cells
The study involved preparations of primary cultures of mouse
proximal tubular cells derived from male C57BL6 mice (Charles
River Laboratories, Saint-Constant, QC, Canada). All mice were
housed according to the Canadian Council on Animal Care
(CCAC) guidelines. The experimental protocols were approved
by the Animal Care Committee at the University of Ottawa (study
protocol ME-2405).
For each experiment, primary cultures of mouse proximal
tubular cells were prepared from 2 male C57BL6 mice (four
kidneys, age of mice 12–16 weeks) by collagenase digestion of
renal cortices followed by Percoll gradient centrifugation, as we
have described (Xiao et al., 2014). After centrifugation in Percoll,
the fourth band (F4), enriched in proximal tubular segments,
was aspirated, suspended in culture medium and centrifuged to
remove the Percoll solution. The final proximal tubular pellet was
suspended in culture medium and seeded onto 35-mm culture
dishes.
Cells were initially grown in a defined medium of DMEM-
F12 (1:1), supplemented with insulin (5 µg/ml), transferrin
(5 µg/ml), selenium (5 ng/ml), hydrocortisone (50 nM), 3,3′,5-
triiodo-L-thyronine (2.5 nM), 100 U/ml penicillin, 100 mg/ml
streptomycin, and 10% fetal bovine serum (FBS). After 24 h, cells
were switched to a defined serum-free medium, with D-glucose
concentration for most experiments set at 7.8 mM. After 4–
5 days, cells reached∼70% confluence and had a typical epithelial
cell morphology. Cells were maintained at 37◦C in a humidified
incubator with 5% CO2/room air, and the medium was changed
every 2–3 days up to the time of experimentation, which was
typically after 7 days in culture.
ACE2 Activity Assay
Angiotensin-converting enzyme 2 activity in cell culture
media was measured using a commercially available synthetic
fluorogenic substrate for ACE2 [Mca-Ala-Pro-Lys(Dnp)-OH]
(AnaSpec, San Jose, CA, USA), as we have described (Xiao et al.,
2012, 2014). After 48–72 h in culture, cell media was collected,
followed by addition of a protease inhibitor cocktail (1% vol/vol)
(Sigma, P8340, St. Louis, MO, USA). For all experiments, media
was first centrifuged at 10,000g for 5 min at 4◦C to remove dead
cells and cellular debris. Cell media (15 µL) was then added
to the wells of a 96-well plate (total volume 100 µL/well) in a
solution containing 37.5 mM 2-(N-morpholino)ethanesulfonic
acid, 225 mM NaCl, 7.5 µM ZnCl2, 0.75 mM N-ethylmaleimide
(NEM), 0.75 mM phenylmethylsulfonyl fluoride (PMSF),
11.25 µM ACE2 substrate, with or without 1 µM of the ACE2
inhibitor MLN-4760 (GL1001, provided by Ore Pharmaceuticals,
Cambridge, MA, USA). Samples were protected from light
and incubated for 16 h on a plate shaker at room temperature
and fluorescence was measured using the FLUOstar Galaxy
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fluorometer (BMG Labtech., Durham, NC, USA) with excitation
wavelength of 320 nM and emission wavelength of 405 nM.
ACE2 activity was determined by subtracting the Relative
Fluorescence Unit (RFU) obtained in the presence of MLN-4760
from the reading in the absence of inhibitor. ACE2 activity in the
culture medium was corrected for the cell protein amounts on
the culture dishes, and is reported as RFUs per µg protein per
hour (RFU/µg/hr).
ACE2 Immunoblot Assays
After centrifugation to remove insoluble debris and dead cells,
cell culture medium was concentrated with the Amicon Ultra-
0.5 30K Centrifugal Filter Devices (EMD Millipore, Darmstadt,
Germany). The concentrate (25 µl) was then prepared in a buffer
consisting of 31.3 mM Tris-HCl (pH 6.8), 1% wt/vol SDS, 5%
glycerol, and 0.025% wt/vol bromophenol blue, and boiled for
5 min. Lysates from proximal tubular cells were prepared in a
buffer consisting of 62.5 mM Tris·HCl (pH 6.8), 2% wt/vol SDS,
10% glycerol, 50 mM DTT, and 0.01% wt/vol bromophenol blue,
boiled for 5 min, and centrifuged at 10,000g for 5 min at 4◦C to
remove insoluble debris.
Twenty-five micro liter of concentrated media (20-fold
concentrate) was run on 7.5% SDS-polyacrylamide gels, and
subjected to immunoblot analysis using commercially available
goat anti-human ACE2 antibodies (1:500 dilution) (AF933,
R&D Systems Inc., Minneapolis, MN, USA) as we previously
described to characterize mouse shed ACE2 fragments by mass
spectrometry (Xiao et al., 2014). Mouse kidney cortex lysates were
used as controls (1.5–10 µg protein). Densitometric analysis of
the protein bands was performed using Kodak ID image analysis
software (Eastman Kodak, Rochester, NY, USA).
RNA Silencing
Transient transfection of proximal tubular cells was performed
with siGENOME SMARTpool silencing (si)RNAs (Dharmacon,
Thermo Fisher Scientific, Waltham, MA, USA) using
LipofectamineTM RNAiMAX Transfection Reagent (Invitrogen,
Carlsbad, CA, USA) as per the manufacturer’s instructions.
Briefly, 60 or 200 pmol scrambled siRNA (Silencer Select negative
control #1), PKC-δ siRNA, or PKC-ε siRNA was added to 250 µl
Opti-MEM R©I Reduced Serum Medium (Invitrogen), then added
to LipofectamineTM RNAiMAX that was diluted in 250 µl Opti-
MEM, and incubated for 10–20 min at room temperature. The
siRNA-LipofectamineTM RNAiMAX complexes were then added
to 35-mm culture dishes containing primary cultures of mouse
proximal tubular cells, achieving final siRNA concentrations of
30 nM or 100 nM. ACE2 activity was assayed in the cell culture
medium, and PKC-δ or PKC-ε protein expression in cell lysates
was assayed by immunoblot 48 h post-transfection.
Materials
D-glucose and L-glucose were obtained from Sigma. The
ADAM17 inhibitor, TNF-α Protease Inhibitor-1 (TAPI-1) was
from Calbiochem (San Diego, CA, USA). Go6976 (PKC-α and
-β1 inhibitor) and matrix metalloproteinase (MMP)–2, –8, and–
9 inhibitors were from EMD Millipore. Ruboxistaurin (PKC-
β1 and -β2 inhibitor) and GI250423X (ADAM10 inhibitor)
were from Tocris Bioscience (Ellisville, MO, USA). Sotrastaurin
(pan-PKC inhibitor) was from Axon Medchem BV (Gronigen,
Netherlands). Rottlerin (PKC-δ inhibitor) was from Santa Cruz
Biotechnology Inc. (Dallas, TX, USA). Phorbol 12-myristate 13-
acetate (PMA) was from Sigma. Antibodies to PKC-δ and -ε
were from Cell Signaling (Danvers, MA, USA). RNA silencing
nucleotides were from Thermo Fisher Scientific (Waltham, MA,
USA). All vehicle controls with use of inhibitors consisted of cells
exposed to an equivalent amount of DMSO (0.05%), which in
preliminary experiments did not affect ACE2 activity in the media
compared to non-DMSO treated cells.
Statistics
Data are presented as mean ± SE. Data were analyzed using
SigmaStat (version 3.5; Systat Software, Inc., San Jose, CA, USA).
For multiple comparisons, analysis was by one-way repeated
analysis of variance followed by Bonferroni correction. For
comparisons involving two groups, Student’s t-test was used.
A p< 0.05 was considered significant.
RESULTS
Effect of D-glucose on ACE2 Shedding in
Mouse Proximal Tubular Cells
Initial experiments determined the concentration-dependent
effect of D-glucose on ACE2 shedding in mouse proximal tubular
cells. As shown in Figure 1A, after 72 h ACE2 activity in the
media rose progressively with increasing concentrations of D-
glucose in the media. This effect was significant at the basal level
of 7.8 mM D-glucose (compared to 0 mM D-glucose), and peaked
at 16 mM D-glucose. In contrast, increasing concentrations of L-
glucose had no effect on ACE2 activity in the media. In separate
experiments, varying concentrations of D-glucose in the media
alone (in the absence of cells) had no effect on ACE2 activity
(n = 6, not shown). By immunoblot, shed fragments of ACE2 at
90 and 70 kDa were detected in the media from proximal tubular
cells, and these fragments each increased with rising D-glucose
concentration (Figure 1B).
Effect of PKC Inhibition on Constitutive
ACE2 Shedding
We studied the role of PKC in regulating ACE2 shedding
in proximal tubular cells incubated under basal D-glucose
conditions (7.8 mM). Incubation of cells with the selective pan-
PKC inhibitor sotrastaurin caused a dose-dependent reduction
in ACE2 activity and protein in media from cells in 7.8 mM D-
glucose (Figures 2A,B). While the ADAM17 inhibitor TAPI-1
(10−5 M) had no effect on constitutive shedding of ACE2 in basal
conditions (7.8 mM D-glucose), it partially blocked stimulation of
shedding induced by high glucose, consistent with our previous
studies (Xiao et al., 2014) (Figure 2C). On the other hand,
sotrastaurin (10−5 M) completely inhibited ACE2 shedding
under conditions of high D-glucose (28 mM), to levels observed
under basal conditions, with or without TAPI-1 (Figure 2C). In
mouse proximal tubular cells maintained in 7.8 mM D-glucose,
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FIGURE 1 | Concentration-dependent stimulation of ACE2 shedding by D-glucose in mouse proximal tubular cells. (A) Graph depicts effect of varying
concentrations of D- or L-glucose on ACE2 activity recovered from cell culture media. ∗P < 0.01 vs. 0, 2, 4, and 7.8 mM D-glucose. ∗∗P < 0.01 vs. 0 mM D-glucose;
n = 4–5. (B) Graph depicts effect of varying concentrations of D-glucose on ACE2 shedding into culture media, determined by immunoblot analysis. Representative
immunoblot is depicted above graph, showing ACE2 fragments at 90 and 70 kDa, with mouse kidney cortex ACE2 at 100 kDa. ∗P < 0.01 vs. 0, 2, 4, and 7.8 mM;
∗∗P < 0.05 vs. 0 and 2 mM; †P < 0.05 vs. 0 mM; n = 5.
administration of the activator of PKC, PMA (10−7 or 10−6 M)
for 30 min increased ACE2 activity in the cell culture media by
192 and 209%, respectively (n= 2 for each).
In contrast to sotrastaurin, neither the PKC-α and -
β1 inhibitor Go6976, nor the PKC-β1 and -β2 inhibitor
ruboxistaurin had any effect on ACE2 shedding in cells incubated
in 7.8 mM D-glucose (Figure 3). Similarly, the ADAM10
inhibitor GI250423X, or inhibitors of MMP-2, -8, or -9 did not
affect ACE2 shedding from proximal tubular cells in 7.8 mM
D-glucose (Figure 4).
Role of PKC-δ in Constitutive ACE2
Shedding
To further probe the role of PKC isoforms in stimulating ACE2
shedding under normal glucose conditions, proximal tubular
cells were incubated with the selective PKC-δ inhibitor rottlerin.
As shown in Figure 5, rottlerin significantly inhibited shedding
of ACE2 fragments, as determined by enzyme activity assay
and immunoblots. Rottlerin also completely blocked stimulation
of ACE2 shedding in high glucose (28 mM). In separate
experiments, incubation of cells in high glucose induced no
significant difference in total cell lysate expression of PKC-δ,
compared to normal glucose (not shown, n = 6). The ADAM17
antagonist TAPI-1 had no effect on ACE2 shedding in 7.8 mM
D-glucose, but inhibited high glucose-mediated ACE2 shedding
(Figure 5C).
RNA silencing was used to further study the role of PKC-
δ in ACE2 shedding. In mouse proximal tubular cells grown
in 7.8 mM D-glucose, silencing of mRNA for PKC-δ was
associated with a modest reduction in protein expression of
PKC-δ, yet this caused a significant (20%) decrease in ACE2
activity in the culture media (Figures 6A,B). By contrast, while
silencing of RNA for the PKC-ε isoform caused a significant
38.5% reduction in protein expression in proximal tubular
cells, this had no effect on ACE2 activity in the culture media
(Figures 6C,D).
DISCUSSION
In this study we investigated the mechanisms for constitutive
proteolytic shedding of ACE2 fragments from mouse proximal
tubular cells. Exposure of cells to increasing concentrations of
D-glucose caused dose-dependent stimulation of shedding of
ACE2 fragments of 90 and 70 kDa. Consistent with our previous
report (Xiao et al., 2014), inhibition of ADAM17 had no effect
on basal ACE2 shedding (7.8 mM D-glucose), but inhibited
high glucose-stimulated shedding (28 mM D-glucose). Here,
using pharmacologic blockade and RNA silencing, we show that
inhibition of PKC-δ significantly blocks both basal- and high D-
glucose-stimulated shedding. The results suggest that PKC-δ is
an upstream regulator of ACE2 shedding in proximal tubular
cells, and is linked to downstream activation of ADAM17 in high
glucose.
Experimental and human diabetes are associated with high
urinary levels of soluble active ACE2 fragments, implicating
a role for ACE2 shedding as a biomarker of disease activity
(Mizuiri et al., 2011; Xiao et al., 2012; Chodavarapu et al.,
2013; Park et al., 2013; Wysocki et al., 2013; Cherney et al.,
2014; Salem et al., 2014). Indeed, in young adults with type 1
diabetes, urinary ACE2 levels are significantly elevated before
development of albuminuria or other clinical complications,
compared to healthy control subjects (Cherney et al., 2014).
The presence of increased urinary ACE2 fragments in the
absence of albuminuria, coupled with evidence that infusion
of recombinant ACE2 in mice with diabetes does not increase
urinary ACE2 levels (Wysocki et al., 2013), suggests that ACE2
shedding from the apical surface of tubular epithelial cells
accounts for a major component of urinary ACE2 content.
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FIGURE 2 | The pan-PKC inhibitor sotrastaurin reduces ACE2 shedding in mouse proximal tubular cells. (A) Graph depicts effect of sotrastaurin
(10-5-10-8 M) on ACE2 activity recovered from cell culture media. ∗P < 0.005 vs. all other groups (C, vehicle-treated control); ∗∗P < 0.05 vs. C and 10−8 M; n = 6.
(B) Graph depicts effect of varying concentrations of sotrastaurin on ACE2 shedding into culture media, determined by immunoblot analysis. Representative
immunoblot is depicted above graph, showing ACE2 fragments at 90 and 70 kDa, with mouse kidney cortex ACE2 at 100 kDa. ∗P < 0.01 vs. all other groups;
∗∗P < 0.05 vs. 10−7 M and vehicle-treated control (C); n = 5. (C) Graph depicts effect of sotrastaurin (10−5 M), with or without the ADAM17 inhibitor TAPI-1 (10−5
M), on ACE2 activity in the culture media, in basal conditions (D-glucose 7.8 mM) or high D-glucose (28 mM). ∗P < 0.01 vs. Control and TAPI-1 (7.8 mM D-glucose);
In D-glucose 28 mM, †P < 0.001 vs. Control and TAPI-1, ††P < 0.05 vs. Control; ‡P < 0.001 vs. Control (D-glucose 7.8 mM); n = 4–5.
FIGURE 3 | Lack of inhibitory effect of the PKC-α and -β1 inhibitor Go6976 (A) and the PKC-β1 and β-2 inhibitor ruboxistaurin (B) on constitutive ACE2
shedding in mouse proximal tubular cells. Graphs depict dose-dependent effects of Go6976 and ruboxistaurin on ACE2 activity in the culture media, compared
to vehicle-treated cells (C); n = 4 experiments each for (A,B).
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FIGURE 4 | Inhibition of ADAM10 or matrix metalloproteinases (MMPs)-2, -8, and-9 has no effect on constitutive ACE2 shedding in mouse proximal
tubular cells. Graphs depict dose-dependent effects of the ADAM10 inhibitor GI250423X (A), MMP-2 inhibitor (B), MMP-8 inhibitor (C), and MMP-9 inhibitor (D) on
ACE2 activity in the culture media, compared to vehicle-treated cells (C); n = 4–5 experiments each for (A–D).
Significantly increased urinary ACE2 levels were reported in
insulin-resistant subjects with impaired fasting glucose, glucose
intolerance, or type 2 diabetes, compared to subjects with normal
glucose tolerance, suggesting a close link between ACE2 shedding
and glucose control (Park et al., 2013). The mechanism for
enhanced urinary ACE2 shedding in diabetes appears to involve
activation of the sheddase ADAM17. In cultured proximal
tubular cells, ADAM17 activity is increased by exposure to high
glucose (Xiao et al., 2014). Renal expression of ADAM17 is
enhanced in experimental models of type 1 and 2 diabetes,
and restoration of normoglycemia inhibits renal ADAM17
expression and reduces urinary ACE2 shedding (Chodavarapu
et al., 2013; Salem et al., 2014). Consistent with these studies,
our results indicate that exposure to high D-glucose stimulates
ACE2 shedding from proximal tubular cells, an effect blocked by
TAPI-1, an inhibitor of ADAM17. The data further suggest the
existence of a glucose concentration threshold for activation of
ADAM17 and stimulation of ACE2 shedding, since blockade of
ADAM17 had no impact on ACE2 shedding under basal glucose
conditions.
Proteolytic shedding of cell surface proteins is a well-described
phenomenon involved in regulation of protein expression and
may result in release of enzymatically active peptide fragments.
Ectodomain cleavage of ACE2 was first described in ACE2-
transfected HEK293 cells and Huh7 cells, and shedding was
stimulated by phorbol esters, an effect blocked by ADAM17
inhibition (Lambert et al., 2005). In agreement with our data,
ADAM17 inhibition had no effect on basal ACE2 shedding
in that study. However, in cultured human airway epithelial
cells, constitutive shedding of soluble ACE2 fragments was
significantly decreased by inhibition of ADAM17 (Jia et al.,
2009) and in COS7 cells stably expressing silencing RNA
constructs against endogenous ADAM17, ACE2 shedding was
reduced (Grobe et al., 2015). Gene deletion of ADAM17
in Chinese Hamster Ovary (CHO) cells and fibroblasts was
associated with reduced constitutive shedding of the larger of
the two soluble ACE2 fragments, an effect that was rescued by
reconstitution of ADAM17 in these cells (Iwata et al., 2009).
These studies highlight the complexity of pathways involved
in proteolytic cleavage of ACE2, which may be affected by
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FIGURE 5 | The PKC-δ inhibitor rottlerin reduces constitutive and high D-glucose-induced ACE2 shedding in mouse proximal tubular cells. (A) Graph
depicts effect of rottlerin (0.01–1 µM) on ACE2 activity recovered from cell culture media, in D-glucose 7.8 mM. ∗P < 0.001 vs. all other groups (C, vehicle-treated
control); ∗∗P < 0.005 vs. C, 0.01 µM, 0.05 µM, and 0.1 µM; n = 5–6. (B) Graph depicts effect of rottlerin (1 µM) on ACE2 shedding into culture media, determined
by immunoblot analysis. Representative immunoblot is depicted above graph, showing ACE2 fragments at 90 and 70 kDa, with mouse kidney cortex ACE2 at
100 kDa. ∗P < 0.05 vs. vehicle treated control (C); n = 4. (C) Graph depicts effect of rottlerin (1 µM), with or without the ADAM17 inhibitor TAPI-1 (10−5 M), on
ACE2 activity in the culture media, in basal conditions (D-glucose 7.8 mM) or high D-glucose (28 mM); ∗P < 0.001 vs. Control and TAPI-1, in D-glucose 7.8 mM;
†P < 0.001 vs. Control, in D-glucose 28 mM; ∗∗P < 0.001 vs. Control (7.8 mM D-glucose); n = 9.
cell-specific regulatory signals, or perhaps ambient glucose
concentration.
In our previous studies in mouse proximal tubular cells, we
demonstrated the presence of two major shed ACE2 fragments
at 90 and 70 kDa, with mass spectrometric identification at
amino acid positions 18–706 and 18–577, respectively, (Xiao
et al., 2014). The appearance of each ACE2 fragment increased
progressively with rising D-glucose concentration in the present
studies, and constitutive shedding of both fragments was reduced
by a pan-PKC inhibitor, but not by inhibitors of isoforms of PKC-
α, -β1, or -β2, ADAM10, or 3 other MMPs. PKC isoforms are
classified into three distinct groups: conventional PKC isoforms
(PKC-α, -β1, -β2, and -γ) are sensitive to diacylglycerol (DAG)
and calcium, novel PKC isoforms (PKC-δ, -ε, -θ, and -η) are
sensitive to DAG but insensitive to calcium, and atypical PKC
isoforms (PKC-ζ, and-ι/λ) are not regulated by DAG or calcium
(Parker and Murray-Rust, 2004). In the present studies, siRNA
against PKC-δ caused a modest 30% reduction in its protein
expression, but this induced a significant decrease in constitutive
ACE2 shedding, while knockdown of PKC-ε had no effect on
shedding. These results support a unique role for PKC-δ in
constitutive ACE2 shedding in these cells, and are consistent with
involvement of PKC-δ in constitutive or phorbol ester-stimulated
shedding of the ectodomain of membrane-bound heparin-
binding EGF in other studies (Izumi et al., 1998; Uchiyama et al.,
2009; Kveiborg et al., 2011). In human myeloma cells, PKC-δ
has also been shown to regulate phorbol ester-induced shedding
of the interleukin-6 receptor (Thabard et al., 2001). Although
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FIGURE 6 | siRNA knockdown of PKC-δ inhibits constitutive ACE2 shedding in mouse proximal tubular cells. (A) Graph depicts effect of transfection of
siRNA against PKC-δ (100 nM) on protein expression of PKC-δ in mouse proximal tubular cells. Results are depicted as PKC-δ protein relative to cells transfected
with scrambled siRNA sequence. Representative immunoblot is shown above graph, with PKC-δ at 78 kDa, and α-tubulin loading control at 50 kDa. ∗P < 0.05;
n = 4. (B) Graph depicts effect of transfection of siRNA against PKC-δ (100 nM) on ACE2 activity in cell culture media. Results are depicted as ACE2 activity relative
to cells transfected with a scrambled siRNA sequence. ∗P < 0.05; n = 4. (C) Graph depicts effect of transfection of siRNA against PKC-ε (30 nM) on protein
expression of PKC-ε in mouse proximal tubular cells. Results are depicted as PKC-ε protein relative to cells transfected with scrambled siRNA sequence.
Representative immunoblot is shown above graph, with PKC-ε at 82 kDa, and α-tubulin loading control at 50 kDa. ∗P < 0.02; n = 6. (D) Graph depicts effect of
transfection of siRNA against PKC-ε (30 nM) on ACE2 activity in cell culture media. Results are depicted as ACE2 activity relative to cells transfected with a
scrambled siRNA sequence; n = 7.
our study did not identify the metalloprotease responsible for
PKC-δ-stimulated basal ACE2 shedding in proximal tubular cells,
potential candidates include ADAM9 and ADAM12, which have
been identified as signaling partners of PKC-δ (Izumi et al.,
1998; Murphy, 2009). Moreover, since inhibition of PKC-δ also
blocked high glucose-induced ACE2 shedding, it is possible that
high glucose-stimulated DAG may be involved in activation of
PKC-δ, and downstream activation of ADAM17 in these cells.
Although we did not detect changes in total cell PKC-δ expression
by immunoblot with high glucose, further studies are necessary
to determine if high glucose stimulates translocation of PKC-δ
from the cytosolic to the plasma membrane fraction in proximal
tubular cells.
The impact of ACE2 shedding from proximal tubular cells on
local degradation of Ang II and generation of Ang-(1–7) is poorly
understood. In this regard, in mice ADAM17-mediated shedding
of ACE2 from brain neurons contributes to the development
of neurogenic hypertension (Xia et al., 2013), suggesting that
preservation of membrane-bound ACE2 may be important in
counteracting local activation of the RAS. Thus, targeting PKC-
δ in proximal tubular cells could represent a strategy to prevent
urinary ACE2 shedding under basal or high glucose conditions,
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thereby maintaining membrane-bound ACE2 as a brake on the
local RAS. Studies in mouse models of diabetes or proteinuria
have shown that genetic deletion of PKC-δ protects renal tubular
cells against apoptosis (Li et al., 2010), and in mice treated
with the nephrotoxin cisplatin, gene deletion or pharmacologic
blockade of PKC-δ reduces kidney injury and tubular cell
apoptosis (Pabla et al., 2011). Accordingly, the potential role of
reduced shedding of ACE2 from proximal tubular cells in these
protective responses merits further study.
In summary, our results indicate that inhibition of PKC-δ
in mouse proximal tubular cells reduces constitutive proteolytic
shedding of ACE2, and blocks high glucose- or ADAM17-
stimulated ACE2 shedding. The data suggest that PKC-δ is a
critical upstream regulator of ACE2 shedding in these cells.
Further in vivo animal studies are required to test the role of
PKC-δ in mediating ACE2 shedding from proximal tubule and
to confirm the in vitro findings presented here.
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